Monitoring Progression of Amyotrophic Lateral Sclerosis Using Ultrasound Morpho-Textural Muscle Biomarkers: A Pilot Study. by Martínez Payá, Jacinto Javier
                             Elsevier Editorial System(tm) for Ultrasound 
in Medicine and Biology 
                                  Manuscript Draft 
 
 
Manuscript Number: UMB-D-17-00412R1 
 
Title: Monitoring progression of Amyotrophic Lateral Sclerosis using 
ultrasound morpho-textural muscle biomarkers: A pilot study.  
 
Article Type: Original Contribution 
 
Keywords: Amyotrophic lateral sclerosis; motor neuron disease; 
neuromuscular Diseases; biomarkers; ultrasonography; disease progression; 
Image Processing Computer-Assisted. 
  
 
 
Corresponding Author: Mr. Jacinto J Martínez-Payá, PhD 
 
Corresponding Author's Institution: Universidad Católica de Murcia 
 
First Author: Jacinto J Martínez-Payá, PhD 
 
Order of Authors: Jacinto J Martínez-Payá, PhD; José Ríos-Díaz, PhD; 
Francesc Medina-Mirapeix; Juan  F Vázquez-Costa; Maria Elena del Baño-
Aledo, PhD 
 
Abstract: There is an increasing need for progression biomarkers, which 
allow the loss of motor neurons in amyotrophic lateral sclerosis (ALS) to 
be monitored in clinical trials. In this prospective longitudinal study, 
muscle thickness, echointensity, echovariation and grey level co-
occurrence matrix textural features are examined as possible progression 
ultrasound biomarkers in ALS patients during a five months' follow-up 
period. Thirteen patients, subjected to three measurements for twenty 
weeks, showed a significant loss of muscle, an evident tendency to loss 
of thickness, and increased echointensity and echovariation. As regards 
textural parameters, muscle heterogeneity tended to increase as a result 
of the neoformation of non-contractile tissue through denervation. Taking 
into account some limitations of the study, the quantitative muscle 
ultrasound biomarkers evaluated showed a promising ability to monitor 
patients affected by ALS. 
 
Suggested Reviewers:  
 
Opposed Reviewers:  
 
 
PhD. Jacinto J. Martínez-Payá 
Health Sciences Department.  
Universidad Católica de Murcia. 
Campus de los Jerónimos s/n  
30107 Guadalupe (Murcia).  
Telf. (34) 968 278 758. Fax. (34) 968 278 820. 
E-mail: jmartinez@ucam.edu 
 
Murcia, Spain September 9th, 2017 
 
Dr. Christy K. Holland 
Ultrasound in Medicine and Biology, 
 
Dear Editor-in-chief: 
 
Enclosed is the manuscript “Monitoring progression of amyotrophic 
lateral sclerosis using ultrasound morpho-textural muscle biomarkers: A 
pilot study”, to your consideration.  
 
The manuscript is a resubmission Ref. Ms. No. UMB-D-17-00412 which includes 
reviewer’s recommendations. Thanks you very much because your comments 
have improved our manuscript. According editorial recommendation we have 
revised our manuscript extensively after giving careful consideration to the 
points that the referees' have made. 
 
We have made a point-by-point response letter and we have added a copy of 
the rewritten manuscript. 
 
 
Please address all correspondence concerning this manuscript to me at 
jmartinez@ucam.edu 
 
Thank you for your consideration of this manuscript.  
 
Sincerely,  
Jacinto J. Martínez-Payá 
Cover Letter
1 
 
We have responded point-by-point to all the comments made by the reviewers pointing 
out where reviewers will be able to find those changes in the text. We have added a 
copy of the rewritten manuscript Ref. Ms. No. UMB-D-17-00412. The title of the 
revised version is, as editor in chief suggested, “Monitoring progression of amyotrophic 
lateral sclerosis using ultrasound morpho-textural muscle biomarkers: A pilot study”. 
 
General Comments 
Reviewers #1 and #2 agreed that there are two important improvements that we need to 
consider: the small size of the cohort (n=13) and the short interval between 
measurements (e.g. 4 weeks vs. 10 weeks).  
 We understand and appreciate the methodological suggestions of both reviewers 
and these improvements will be undoubtedly included in future studies. 
 The aim of this pilot study was to develop a proof of concept of the potential 
value of several ultrasound biomarkers, obtained with a new methodology, in the 
evaluation of ALS progression. Previous studies concluded that ultrasonography 
was not suitable to monitor disease progression. However, in our study, several 
ultrasound biomarkers emerge as candidates for progression monitoring. Of 
course, these results must be validated in large-scale and long follow-up studies, 
but we think that our results are a good starting point for future research. 
 
Introduction 
Reviewer #1 wrote: “The introduction should include mention of electrical impedance 
myography in ALS.” 
 We have included it (page 3; line 8-13) and we have added the following 
reference:  
 Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David 
WS, Goyal N, Maragakis NJ, Clawson L, Benatar M, Usher S, Sharma 
KR, Gautam S, Narayanaswami P, Raynor EM, Watson ML, Shefner 
JM. Electrical impedance myography as a biomarker to assess ALS 
progression. Amyotroph Lateral Scler 2012;13:439–445. 
 
Reviewer #2 suggested these two minor changes:  
- Line 3: Please change "upper (UMN) and lower (LMN) motor neurons" to "upper 
motor neurons (UMN) and lower motor neurons (LMN)". 
- Line 8: Please change "incorporatedin" to "incorporated in". 
 We have made these changes in the main document on page 1, lines 3 and 8 
respectively. 
 
Methods 
Reviewer #1 asked: If the patients were recruited September 2013-April 2014 and 
follow-up was only 20 weeks, why the 3-year delay to analysis/publication? 
 After the follow-up, the image analysis was performed, the database was 
constructed and we completed the statistical analysis. We spent almost one year 
*Detailed Response to Reviewers
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in all these actions because the members of this research team do not dedicate 
themselves exclusively to research, but combine this work with university 
teaching and / or clinical practice. 
 This paper is the third and last in a series of papers in which we present and 
discuss the results of the “Longitudinal ultrasound study of muscular 
degeneration in patients with amyotrophic lateral sclerosis”. To avoid 
overlapping the information and analysis we have had to wait for the journals to 
publish the two previous ones, which explains why the delay between data 
analysis period and publication is almost 2 years. 
 
Reviewer #1 also asked: Similarly, why were the patients not followed for more than 20 
weeks? 
 A longer period of follow-up would have been desirable but our initial sample 
was small and patients were in a moderate to advanced stage ALS, limiting the 
ability of long follow-up.  
 Moreover, progression biomarkers are of especial interest to shorten the duration 
of clinical trials and make them more efficient. Therefore, a good progression 
biomarker should be able to find changes within 20 weeks, which is 
approximately the duration of many phase I and II trials in ALS. Consequently, 
we thought that, for a pilot study, this duration should be enough to find 
differences.  
 Finally, previous studies had similar periods of follow-up: 
  Arts IMP, Overeem S, Pillen S, Schelhaas HJ, Zwarts MJ. Muscle 
changes in amyotrophic lateral sclerosis: a longitudinal ultrasonography 
study. Clinical neurophysiology 2011;122:623–8. 
 Lee CD, Song Y, Peltier AC, Jarquin-Valdivia AA, Donofrio PD. Muscle 
ultrasound quantifies the rate of reduction of muscle thickness in 
amyotrophic lateral sclerosis. Muscle & nerve 2010;42:814–9. 
 
Reviewer #1 wrote: The Cartwright et al. reference is not the appropriate citation for 
the ALSFRS-r.  Please cite the source reference (J Neurol Sci. 1999 Oct 31;169(1-
2):13-21.)  Also check references for the MRC global score. 
 We agree with the reviewer that the cited reference was erroneous. We have 
corrected it and we have added these appropriate references in the text (page 5, 
lines 16 and 18): 
 Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, 
Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that 
incorporates assessments of respiratory function. BDNF ALS Study 
Group (Phase III). J Neurol Sci 1999;169:13–21.  
 Florence JM, Pandya S, King WM, Robison JD, Baty J, Miller JP, 
Schierbecker J, Signore LC. Intrarater reliability of manual muscle test 
(Medical Research Council scale) grades in Duchenne’s muscular 
dystrophy. Physical therapy 1992;72:115-22–6. 
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Reviewer #1 asked: Was there any blinding of image acquisition performed in the 
current study?  This is a potential source of bias. 
 Researchers who acquired and analyzed the images were blinded for diagnosis. 
We added this information in the document (page 5; lines 22). 
 
Reviewer #1 wrote: Please provide more detail on how the ROI was selected. Were 
more superficial or deep areas favoured?  Was there a bias toward including the most 
affected areas? 
 We select the ROI in the most reflective region avoiding anisotropic zones and 
minimizing the risk of loss of the most affected areas.  
 In a previous published study, we demonstrated that the method of ROI selection 
was reproducible and valid. Reference of this reliability study has been included 
in the text (page 6; lines 20-21). . 
 
Results/Discussion 
Reviewer #1 wrote: The number of patients lost to follow-up is of concern.  Analysis 
show that these were the most affected patients, which is not surprising.  However, the 
muscle will be more affected in these patients and less likely to show change (e.g. "End-
stage muscle"). We have seen this in some older Duchenne muscular dystrophy patients, 
making longitudinal assessments challenging. 
 We absolutely agree. The advanced state of patients entering the study is a 
limitation of the present investigation and future studies will be undoubtedly 
focused in early stage patients. However, as we have explained above, the aim of 
this pilot study was to develop and test a new ultrasound monitoring method. As 
we emphasize in the strengths and limitation section “larger studies assessing 
longitudinal changes in muscle EV from diagnosis to an advanced stage are 
warranted to confirm our results and hypotheses and to establish the role of EI, 
EV and GLMC as progression and prognostic biomarkers” (page 13, lines 20-
23). 
 
Reviewer #1 wrote: Upon reading the results section, it is unclear if EI and GLCM 
changed prior to onset of clinical change or if the change was delayed as with MTh. 
Table 4 makes this clearer, but please clarify in the text. 
 We agree with this concern and we have included a paragraph in the text to 
clarify the information provided in tables 4 and 5 (now tables 2 and 3) (page 9; 
lines 9-15 and page 11; lines 15-18). 
 
Reviewer #1 wrote: A primary weakness of this approach, similar to all studies on 
muscle ultrasound, is that these are derived measures and the images are often highly 
anisotropic. How does the current approach offer advantages or measuring echointensity 
alone?  How might this approach hold up to intra-observer and inter-observer agreement 
analysis - not only for obtaining the image, but selecting the ROI? 
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 The echovariation and textural parameters add information about the granularity 
of the muscle compared to the analysis of the echointensity. We have shown the 
advantages of these measurements in ALS patients in previous articles: 
Ultrasound Med Biol 2017;43:1153–1162 / Ultrason Imaging 2017; In press.  
DOI: 10.1177/0161734617711370. However, since each parameter measures 
different properties of the muscle and each muscle display different echographic 
characteristics depending on its function or the stage of the disease, it is possible 
that different biomarkers show the best performance according to the studied 
muscle and the stage of the disease. Larger studies are warranted to address this 
issue. 
 In previous published studies we have studied the reliability and reproducibility 
of the ROI selection method, obtaining very good ICC values. Ultrasound Med 
Biol 2017;43:1153–1162 / Ultrason Imaging 2017; In press.  DOI: 
10.1177/0161734617711370. 
 
Reviewer #1 wrote: More information is needed on the conflicting results presented on 
page 12, paragraph 2. The current results are in opposition with the authors' earlier 
publication on this topic. The explanation provided is very short and hypothetical. 
Thank you for the recommendation. Our apparently contradictory results suggest that 
changes in textural parameters (unlike EI) vary with disease progression, with an initial 
decrease of tissue heterogeneity and granularity, followed by a gradual increase. 
Increases in EI found in ALS patients have been previously interpreted as a result of 
fibrotic and fatty tissue formation after muscle denervation, since these tissues are more 
echointense than muscle (Caresio et al. 2015). However, the first muscle change during 
the course of denervation, is an edemalike phase. This phase is characterized by an 
increase of both T1 and T2 relaxation times in muscle MRI (Bryan et al. 1998). With 
advanced denervation, muscle is replaced by fat and fibrotic tissue, which is 
characterized by a decrease in T1 relaxation time, and a further increase in the T2 
relaxation time. Thus, during the progressive stages of muscle denervation, the T2 
relaxation time increases continuously, whereas the T1 relaxation time increases and 
then decreases (Bryan et al. 1998). We think that something similar happens with 
muscle biomarkers. The initial increase in EI and decrease in homogeneity and 
granularity are due to this edemalike phase, which explains that ALS patients show less 
homogeneity and granularity than controls. However, as the disease progresses and 
muscle tissue is progressively replaced by fat and fibrotic tissue, the formation both 
non-contractile tissues would decrease the homogeneity, while the EI continues to 
increase. Moreover, the fatty tissue is more echointense than the fibrotic one (Walker 
and Cartwright 2011) which means that the degree of irregular distribution of both non-
contractile tissues would affect muscle texture in a different degree in each muscle 
group. These phenomena would explain the diversity of changes in EV, granularity and 
contrast found in different muscle groups, since each might be in a different denervation 
stage and with a variable proportion of fatty and fibrotic tissue infiltration. However, 
given the limitations of our study, more studies on muscle textural biomarkers are 
needed to figure out in more detail the dynamics of change of muscle biomarkers during 
the disease progression. 
 For further explanation of this point, we have included a paragraph in the main 
document (page 12, lines 8-25 and page 13, lines 1-13). 
5 
 
 
Figures and Tables 
Reviewer #1 suggested that tables 2 and 3 not additive to the text and might be deleted 
or provided as supplementary material. 
 As suggested, we have removed tables 2 and 3 from the main document by 
enclosing them as supplementary material. 
 In the Results section we have changed the number of the remaining tables and 
we have pasted the description of the tables to the end of the section (page 9, 
line 13-22). 
 
 
 
 
 
 
1 
 
TITLE: Monitoring progression of Amyotrophic Lateral Sclerosis using ultrasound morpho-1 
textural muscle biomarkers: A pilot study. 2 
 3 
Authors: Jacinto J. Martínez-Payá
1
 (PhD), José Ríos-Díaz
2,3
 (PhD), Francesc Medina-4 
Mirapeix
4
 (PhD), Juan F. Vázquez-Costa 
5,6,7
 (MD), María Elena del Baño-Aledo
4
 (PhD). 5 
 6 
Author affiliation: 7 
1
 ECOFISTEM Research Group, Health Sciences Department, Facultad de Ciencias de la 8 
Salud, Universidad Católica de Murcia. Campus de los Jerónimos s/n 30107 Guadalupe 9 
(Murcia) Spain.
  
10 
2 
Centro Universitario de Ciencias de la Salud San Rafael-Nebrija, Paseo de la Habana.  11 
3 
Fundación San Juan de Dios, Madrid, Spain. 12 
4 
Physiotherapy Department, Facultad de Medicina, Campus de Espinardo 30100, Universidad 13 
de Murcia, Spain. 14 
5 
Department of Neurology, Hospital Universitario y Politécnico La Fe, Avenida Fernando 15 
Abril Martorell, nº106, 46026 Valencia, Spain. 16 
6
 Neuromuscular and Ataxias Research Unit, Instituto de Investigación Sanitaria la Fe (IIS La 17 
Fe), Avenida Fernando Abril Martorell nº 106 Torre A-7ª planta, 46026 Valencia, Spain. 18 
7
 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain. 19 
 20 
 21 
Corresponding author: PhD Jacinto J. Martínez-Payá. Health Sciences Department, 22 
Facultad de Ciencias de la Salud. UCAM. Campus de los Jerónimos s/n 30107 Guadalupe 23 
(Murcia). Tel. (+34) 968 278758. E-mail: jmartinez@ucam.edu. 24 
 25 
  26 
*Manuscript
Click here to view linked References
 
 
2 
 
ABSTRACT. 1 
There is an increasing need for progression biomarkers, which allow the loss of motor 2 
neurons in amyotrophic lateral sclerosis (ALS) to be monitored in clinical trials. In this 3 
prospective longitudinal study, muscle thickness, echointensity, echovariation and grey level 4 
co-occurrence matrix textural features are examined as possible progression ultrasound 5 
biomarkers in ALS patients during a five months’ follow-up period. Thirteen patients, 6 
subjected to three measurements for twenty weeks, showed a significant loss of muscle, an 7 
evident tendency to loss of thickness, and increased echointensity and echovariation. As 8 
regards textural parameters, muscle heterogeneity tended to increase as a result of the 9 
neoformation of non-contractile tissue through denervation. Taking into account some 10 
limitations of the study, the quantitative muscle ultrasound biomarkers evaluated showed a 11 
promising ability to monitor patients affected by ALS. 12 
 13 
Keywords: Amyotrophic lateral sclerosis; motor neuron disease; neuromuscular Diseases; 14 
biomarkers; ultrasonography; disease progression; Image Processing Computer-Assisted. 15 
  16 
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INTRODUCTION. 1 
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder affecting 2 
both upper motor neurons (UMN) and lower motor neurons (LMN), leading to gradual 3 
muscle weakness and wasting (Wijesekera and Leigh 2009). The variable degree of 4 
impairment of UMN and LMN results in pathological and clinical heterogeneity, which 5 
hinders diagnosis, prognosis and the monitoring of progression (Kinsley and Siddique 1993). 6 
Electromyography allows LMN impairment to be detected before the onset of overt 7 
symptoms and consequently has been incorporated in successive diagnostic criteria (Brooks et 8 
al. 2000). However, despite some promising new neurophysiological techniques such as 9 
MUNIX (Neuwirth et al. 2015) and electrical impedance myography (Rutkove et al. 2012), 10 
clinical tools such as Medical Research Council (MRC) (Florence et al. 1992) and the revised 11 
ALS functional rating scale, (ALSFRS-r) (Simon et al. 2014) remain the gold standard 12 
biomarkers for progression monitoring in clinical trials or clinical practice. 13 
Muscle ultrasonography (MUS) is an accessible, painless and easy to perform method to 14 
detect structural muscle changes in ALS (Mayans et al. 2012). More specifically, MUS 15 
reveals marked diminished muscle thickness (MTh), increased echointensity (EI) and 16 
fasciculations (Arts et al. 2012; Martínez-Payá et al. 2017a). However, in a longitudinal study, 17 
Arts et al. (2010) observed that these ultrasound changes found in ALS patients were highly 18 
variable and did not show evident correlation with functional measures like muscle strength or 19 
disability during 6 months monitoring (Arts et al. 2011a). 20 
We have previously described a new first-order ultrasound biomarker, echovariation (EV), 21 
which distinguished the muscles of ALS patients from healthy controls, with higher effect 22 
sizes than MTh or EI and correlating better with other clinical variables (Martínez-Payá et al. 23 
2017a).  24 
 
 
4 
 
While EV is a fast and easy method to obtain information on tissue homogeneity (Aggarwal 1 
and Agrawal 2012), it does not provide information concerning the relative positions of the 2 
various grey levels within the image. This issue can be resolved by a second-order statistics 3 
features based on the grey level co-occurrence matrix (GLCM), where the pixels are 4 
considered in pairs. GLCM detects the relationship between neighbouring pixel intensities 5 
and provides information about grey level patterns (Haralick et al. 1973). Moreover, GLCM 6 
parameters showed reduced granularity in the muscles of ALS patients compared with 7 
controls and a similar discrimination capacity to EV (Martínez-Payá et al. 2017b). 8 
However, the usefulness of the textural features of EV and GLCM as progression biomarkers 9 
has not been analysed. Hence, we designed a prospective longitudinal study in patients with 10 
ALS to evaluate these new biomarkers and compare them with MTh and EI, during a follow-11 
up period of 20 weeks.  12 
 13 
 14 
15 
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MATERIAL AND METHODS. 1 
Subjects. 2 
Patients were recruited from the ALS Association (ADELA) of Valencia (Spain) between 3 
September 2013 and April 2014. Twenty-six patients diagnosed with ALS according to the 4 
revised El Escorial Criteria (Brooks et al. 2000) by an experienced neurologist (JFVC) were 5 
included. The same cohort had been used previously to assess changes in EV and GLMC 6 
between patients (at recruitment) and controls (Martínez-Payá et al. 2017a; Martínez-Payá et 7 
al. 2017b). For this longitudinal study, each patient was evaluated twice more with an interval 8 
of 10 weeks ± 7 days. 9 
Standard protocol approval, recruitment, and patient consent. 10 
This study was approved by the Ethics Committee of the Universidad Católica de Murcia 11 
(Spain). All participants provided written informed consent.  12 
Recorded variables. 13 
Demographical and clinical characteristics (sex, age, weight, height, body mass index, time 14 
from diagnosis) were recorded. Muscle strength was measured using the MRC global score 15 
with a maximum value of 100 (Florence et al. 1992), as described and segmented by upper 16 
(max. 50) and lower limbs (max. 30) and neck muscles (max. 20). The ALSFRS-r rating scale 17 
(Cedarbaum et al. 1999), was assessed by the same investigator (JM-P) on the same day as the 18 
MUS was performed. 19 
Ultrasonography. 20 
MUS was performed in four muscle groups of each side by the same experienced examiner 21 
(JM-P) blinded for the diagnosis, with a phased array real-time scanner  LOGIQe BT12 22 
(General Electric Healthcare, China) and a 513 MHz linear array transducer (12LRS) as 23 
previously published (Martínez-Payá et al. 2017a; Martínez-Payá et al. 2017b). 24 
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Applying the standardized protocol described (Arts et al. 2011a; Martínez-Payá et al. 2017a), 1 
bilateral transverse ultrasound images of the biceps/brachialis, forearm flexors group, 2 
quadriceps femoris and tibialis anterior were obtained and measured. Three images were 3 
taken of every muscle in order to minimize variation in measurement parameters (Arts et al. 4 
2008). 5 
The resulting images had a resolution of 820 x 614 pixels (with a scale of 99.5px/cm for 6 
tibialis anterior muscle and 83.5px/cm for other muscles) involving 256 grey levels, and were 7 
stored as TIFF files without compression or loss (Wiggins et al. 2001). 8 
Image analysis.  9 
MTh was measured with electronic calipers as previously described (Arts et al. 2010; 10 
Martínez-Payá et al. 2017a; Martínez-Payá JJ et al. 2017b). This parameter was measured in 11 
all three images of each muscle group by an expert ultrasonographer (JM-P) and the mean of 12 
the three values was used for the corresponding analysis. 13 
The image processing and analysis was performed by one researcher (JR-D), blind to 14 
diagnosis, using the ImageJ (v.1.48, National Institute of Health, Bethesda, Maryland, USA, 15 
2015) software. The region of interest (ROI) was selected with the ROI Manager application 16 
for ImageJ, with a size of 71 x 40 pixels for tibialis anterior and 73 x 73 pixels for other 17 
muscle groups on an 8-bit grey scale. The ROI was defined as the muscle region without bone 18 
and fascia with the best reflection (Martínez-Payá et al. 2017a; Martínez-Payá et al. 2017b) 19 
(Figure 1). This ROI selection method has been found reproducible and valid in a previous 20 
study. (Martínez-Payá et al. 2017a). From the ROI we obtained EI, EV (Martínez-Payá et al. 21 
2017a) and GLCM (Martínez-Payá JJ et al. 2017b) textural features. 22 
The texture analysis based on a GLCM is derived from the angular relationship between 23 
neighbouring pixels (Nanni et al. 2013), among which five parameters were selected: Energy 24 
or Angular Second Moment (ASM); Textural correlation (TC); Homogeneity or Inverse 25 
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Difference Moment (IDM); Contrast (CON) and Entropy (ENT). A homogeneous image 1 
would be the result of a greater ASM/TC/IDM and a smaller CON/ENT. 2 
Statistical analysis. 3 
Data were analysed using IBM SPSS Statistics for Windows 19.0 (IBM Corp. Released 2010, 4 
Armonk, NY, USA). Data were summarized by mean, standard deviations, range and 95% 5 
confidence intervals for continuous variables and absolute and relative frequencies for 6 
categorical variables. Significance was fixed at 0.05 in all the statistical tests.  7 
The follow-up group with 3 measurements (initial, 10
th
 week and 20
th
 week) was compared 8 
with the lost to follow-up group at baseline with a one-way analysis of variance (ANOVA) for 9 
continuous variables and chi-squared test for categorical variables. 10 
All continuous variables were distributed normally and thus the ANOVA assumptions were 11 
not violated. A repeated measures ANOVA was used to compare the effect of time (three 12 
levels) on MRC, ALSFRS-r, EI, EV, and the five GLCM textural features. The Mauchly test 13 
was used to evaluate the assumption of sphericity, in case it was violated; a Greenhouse-14 
Geisser corrected test for degrees of freedom was performed. Univariate paired post-hoc t-test 15 
(with Bonferroni correction) analyses for each dependent measure with respect to baseline 16 
were performed. 17 
Cohen’s d statistic (taking the SD at baseline as reference) was used to determine the effect 18 
size in pairwise comparisons (< 0.1 small, 0.25 medium and > 0.4 large effect size) (Kelley 19 
and Preacher 2012). To compare ultrasound parameters of various muscles, besides ALSFRS-20 
R and MRC scores for the 20 weeks, the percentage change from baseline was calculated for 21 
each parameter. 22 
 23 
  24 
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RESULTS. 1 
Study subject’s characteristics. 2 
Twenty-six patients with ALS (8 women) were included in this study and 13 patients were 3 
lost to follow-up (6 deaths and 7 due to high disability that prevented the ultrasound study). 4 
Therefore, 13 patients were followed for 20 weeks (2 women, mean age 56.3 years, SD 10.41) 5 
(Table 1).  6 
Follow-up vs lost to follow-up cohort. 7 
The clinical and ultrasound characteristics of the first measurement were compared between 8 
patients who finished all three measurements and the patients lost to follow-up. 9 
Differences in demographical and clinical characteristics between both cohorts can be found 10 
in Table 1. As expected, patients lost to follow-up were more disabled, had less muscle 11 
strength and a longer disease duration since diagnosis. 12 
Quantitative muscle ultrasound biomarkers and progression monitoring in ALS. 13 
A significant decrease in muscle strength and ALSFRS-r rating scale was evident at the first 14 
and second follow-up (Table 2). The mean of the MRC global values and ALSFRS-r score 15 
had fallen by about 20% at week 20 (approx. 1%/week) with a rate of change of -0.55 16 
points/week (max. 100) and -0.33 points/week (max 48), respectively. The decrease in MRC 17 
in lower limbs was similar in both follow-up measurements. Conversely, in upper limbs, the 18 
decrease in MRC occurred predominantly between the 10th and 20th week (Table 2).  19 
We observed consistent changes with time in the first-order MUS biomarkers (Table 2). MTh 20 
showed a trend to decrease in all muscle groups but with a low effect size (≤0.43) and rate of 21 
change (-0.4%/week). Moreover, this decrease was not linear and occurred late (between the 22 
second and third measurements). Conversely, EI increased and showed a greater rate of 23 
change (1.1%-1.3%/week) and effect sizes (1.22-1.49) than clinical variables, except for 24 
tibialis anterior. Moreover, changes in EI were similar in both follow-up measurements, 25 
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suggesting a linear increase. EV tended to increase in all muscle groups, except biceps 1 
brachialis. However, greater heterogeneity in effect sizes and rates of change was found 2 
depending on muscle groups and the follow-up time. 3 
Regarding GLCM textural parameters, most of them showed significant changes with time, 4 
ASM/TC/IDM decreasing and CON/ ENT increasing (Table 3). Although effect sizes and rate 5 
of change of each parameter varied as per muscle group, overall CON was the parameter 6 
showing the greatest effect sizes (0.35-1.08) and rates of change (between 1.4 and 7 
3.3%/week).  8 
MTh of all muscles showed similar or worse size effects in both measurements than the 9 
respective clinical variables. However, compared with ALSFRS-r, all biomarkers except IDM 10 
showed greater effect sizes in at least one muscle of the lower and upper limbs. Compared 11 
with the MRC in upper limbs, all biomarkers except EV and CON, showed better effect sizes 12 
in both upper limbs muscles. Finally, in lower limbs, all biomarkers except IDM showed 13 
better effect sizes than MRC in quadriceps, but not in tibialis anterior, suggesting that muscle 14 
changes are more evident in those more preserved ones. 15 
Differences in first-order MUS variables between cohorts were also analysed (Supplementary 16 
Table 1). We observed a lower MTh and a greater EI in most evaluated muscles in the lost to 17 
follow-up cohort. Quadriceps femoris was the muscle showing greatest differences, whereas 18 
no relevant differences were found in forearm flexor. Greater EV in the quadriceps femoris 19 
was found in the lost to follow-up group, but no differences in EV in other muscle groups. 20 
Analyses of GLCM textural features showed that, again, quadriceps femoris presented the 21 
greatest differences (lower ASM, TC and IDM and a greater CON and ENT in the lost to 22 
follow-up group), whereas no differences were found in the upper limb muscle groups 23 
(Supplementary Table 2). 24 
 25 
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DISCUSSION. 1 
We have previously described an increased EI and reduced MTh, EV and granularity (i.e. 2 
reduced muscle heterogeneity) in ALS patients compared with healthy controls (Martínez-3 
Payá et al. 2017a; Martínez-Payá et al. 2017b). MTh is a measure of muscle atrophy, which is 4 
a well-known feature of ALS. EI measures the mean pixel intensity of an ROI and has been 5 
shown to increase in ALS patients (Arts et al. 2008; Martínez-Payá et al. 2017a) probably due 6 
to the infiltration of fatty and connective tissue after neurogenic denervation (Pillen et al. 7 
2009). EV is a parameter that quantifies the deviation of the level of grey from the average, 8 
and is the result of dividing the standard deviation by the mean pixel intensity (EI), thus 9 
providing information on tissue homogeneity (greater EV reflects greater tissue 10 
heterogeneity). GLMC variables investigate the relationship between neighbouring pixel 11 
intensities (Haralick et al. 1973) and provide information about grey level patterns 12 
(granularity) (Gdynia et al. 2009).  13 
Study design. 14 
In this longitudinal study, the evolution of all these quantitative MUS parameters as the 15 
disease progressed was analysed in the same cohort of ALS patients (Martínez-Payá et al. 16 
2017a; Martínez-Payá et al. 2017b).  17 
Half of the patients were lost to follow-up due to poor short-term prognosis (death or 18 
increasing disability that prevented continuing in the study). As expected, lost to follow-up 19 
patients were more disabled at recruitment. Interestingly, they showed lower MTh and greater 20 
EI than the follow-up cohort. Although our study was not designed to evaluate MUS as a 21 
prognosis biomarker, these results reinforce previous findings by Arts et al. (2011) who found 22 
that EI predicts prognosis (Arts et al. 2011b). Greater differences between groups were found 23 
in the lower limb muscles, which could be because more patients in the lost to follow-up 24 
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group had a lower limb onset. No significant differences between groups were found in EV 1 
and GLMC, except as regards quadriceps femoris, where the follow-up cohort showed 2 
reduced heterogeneity. However, the effect sizes of each biomarker varied considerably 3 
according to the muscle group, suggesting that differences both in the muscle characteristics 4 
and in the degree of impairment influence MUS biomarkers. 5 
Quantitative MUS parameters as progressions biomarkers. 6 
ALS is characterized by a great heterogeneity in the disease onset and spread (Ravits and La 7 
Spada 2009), which results in a variable degree of muscle impairment, depending on the 8 
region of onset, the spread of the disease and the muscle group studied in each single region. 9 
This hinders an accurate measurement of disease progression in clinical trials. The patients 10 
followed in this longitudinal study are representative of those usually included in clinical 11 
trials, namely patients in a moderate stage of the disease with at least two body regions 12 
affected. Despite this disease-related heterogeneity and the low number of studied subjects, 13 
we were able to find consistent changes as the disease progressed in all the studied MUS 14 
biomarkers. Moreover, although decreases in MTh were mild and late, a linear variation with 15 
greater effect sizes than that of clinical variables (ALSFRS-r and MRC) was observed in most 16 
first and second order parameters. Among all, EI showed the greater effect sizes in most 17 
muscles. This suggests that EI (a measure of fatty and connective tissue infiltration) is more 18 
sensitive to changes with disease progression than clinical variables. Surprisingly, Arts et al. 19 
(2011) previously failed to find changes in EI and MTh with disease progression (Arts et al. 20 
2011a), whereas Lee et al. (2010) found changes in MTh but not in EI (Lee et al. 2010). Both 21 
studies included a small number of patients and any divergences from our results are probably 22 
attributable to methodological differences.  23 
Regarding EV, a gradual increase in forearm flexor and quadriceps femoris muscle groups but 24 
not in biceps/brachialis and tibialis anterior was found for this parameter, reflecting an 25 
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increase in tissue heterogeneity with disease progression and agreeing with the increased 1 
muscle heterogeneity reported in qualitative visual assessment following neurogenic 2 
denervation (Pillen et al. 2008).  3 
Similar to EV, GLMC parameters showed a progressive increase in tissue granularity and 4 
contrast with disease progression, The textural variable most sensitive to changes was CON, 5 
although as with EV, differences were not statistically significant in biceps brachialis and 6 
tibialis anterior.  7 
These results appear to conflict with our previous findings of reduced EV, granularity and 8 
contrast in ALS patients compared with healthy controls (Martínez-Payá et al. 2017a; 9 
Martínez-Payá et al. 2017b). These apparently contradictory results suggest that changes in 10 
these biomarkers (unlike EI) vary with disease progression, with an initial decrease of tissue 11 
heterogeneity and granularity, followed by a gradual increase. Increases in EI found in ALS 12 
patients have been previously interpreted as a result of fibrotic and fatty tissue formation after 13 
muscle denervation, since these tissues are more echointense than muscle (Caresio et al. 14 
2015). However, the first muscle change during the course of denervation, is an edemalike 15 
phase. This phase is characterized by an increase of both T1 and T2 relaxation times in 16 
muscle MRI (Bryan et al. 1998). With advanced denervation, muscle is replaced by fat and 17 
fibrotic tissue, which is characterized by a decrease in T1 relaxation time, and a further 18 
increase in the T2 relaxation time. Thus, during the progressive stages of muscle denervation, 19 
the T2 relaxation time increases continuously, whereas the T1 relaxation time increases and 20 
then decreases (Bryan et al. 1998). We think that something similar happens with muscle 21 
biomarkers. The initial increase in EI and decrease in homogeneity and granularity are due to 22 
this edemalike phase, which explains that ALS patients show less homogeneity and 23 
granularity than controls. However, as the disease progresses and muscle tissue is 24 
progressively replaced by fat and fibrotic tissue, the formation both non-contractile tissues 25 
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would decrease the homogeneity, while the EI continues to increase. Moreover, the fatty 1 
tissue is more echointense than the fibrotic one (Walker and Cartwright 2011) which means 2 
that the degree of irregular distribution of both non-contractile tissues would affect muscle 3 
texture in a different degree in each muscle group. These phenomena would explain the 4 
diversity of changes in EV, granularity and contrast found in different muscle groups, since 5 
each might be in a different denervation stage and with a variable proportion of fatty and 6 
fibrotic tissue infiltration. 7 
Our results, together with those previously published (Martínez-Payá et al. 2017a; Martínez-8 
Payá et al. 2017b) suggest that EI would be the best muscle biomarker to monitor disease 9 
progression changes (at least in late disease stages), since it continuously increases throughout 10 
the disease course. However, textural parameters would discriminate better early muscle 11 
changes and would therefore perform better as diagnostic biomarkers (Martínez-Payá et al. 12 
2017a; Martínez-Payá et al. 2017b). 13 
Strengths and limitations. 14 
To the best of our knowledge, our study represents the most thorough analysis to date of 15 
muscle biomarkers to assess disease progression in ALS patients. Moreover, the highly 16 
reliable methodology identified consistent changes in muscle biomarkers with disease 17 
progression, where others failed (Arts et al. 2011a; Lee et al. 2010). However, the studied 18 
sample was small, patients were in a moderated to advanced stage of the disease and follow-19 
up was limited to 20 weeks. Therefore, larger studies assessing longitudinal changes in 20 
muscle EV from diagnosis to an advanced stage are warranted to confirm our results and 21 
hypotheses and to establish the role of EI, EV and GLMC as progression and prognostic 22 
biomarkers. 23 
 24 
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CONCLUSIONS. 1 
Our pilot study suggests that, unlike previously found, quantitative MUS parameters are 2 
feasible progression biomarkers in ALS and could be more sensitive than clinical variables for 3 
monitoring progression. In moderately disabled ALS patients, disease progression results in a 4 
decrease in MTh, and an increase in EI and in muscle heterogeneity (measured with both EV 5 
and GLMC monitoring parameters). Overall, EI appears to be the most sensitive and reliable 6 
biomarker for progression in a moderate to advanced disease stage. Changes in muscle 7 
homogeneity and granularity differ according to muscle group and disease stage, which could 8 
reflect distinct denervation phases. 9 
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FIGURE CAPTIONS 1 
Figure 1. Analysis of thickness and echotexture in the biceps/brachialis muscle group in ALS 2 
patients after a follow-up of 20 weeks. In this patient, we observed a loss of 25% of muscle 3 
thickness and an increase of 26% of the muscle echointensity (ROI A. 74 points vs ROI B. 98 4 
points). 5 
  6 
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TABLES. 1 
Table 1. Baseline differences between patients subjected to 3 measurements and lost patients. 2 
Baseline characteristics Follow-up cohort (n=13) Lost to follow-up cohort (n=13) p-value 
Women (n) (%) 2 (15.4 %) 6 (46.2 %) 0.016 
Age (yr) 56.3 (10.41); 52.1 to 60.5 60.9 (11.46); 56.3 to 65.6 0.137 
Weight (kg) 66.9 (14); 61.3 to 72.6 68.6 (17.22); 61.7 to 75.6 0.699 
Height (m) 1.7 (0.075); 1.67 to 1.73 1.62 (0.074); 1.59 to 1.65 0.001 
BMI (kg/m^2) 23 (3.6); 21.6 to 24.5 25.8 (4.98); 23.7 to 27.8 0.027 
Disease onset-diagnosis (months) 14.1 (9.01); 10.5 to 17.8 18.5 (10.43); 14.3 to 22.7 0.115 
Region of onset (n) (%)    
Right Lower Limb 3 (23.1 %) 6 (46.2 %) 
0.321 
Left Lower Limb 3 (23.1 %) 2 (15.4 %) 
Right Upper Limb 1 (7.7 %) 0 (0 %) 
Left Upper Limb 2 (15.4 %) 2 (15.4 %) 
Bulbar 4 (30.8 %) 3 (23.1 %) 
ALFSFR-r (max. 48) 29.3 (11.92); 24.5 to 34.1 23 (10.72); 18.7 to 27.3 0.050 
MRC (max. 100) 62.9 (19.72); 54.9 to 70.8 54.2 (28.66); 42.6 to 65.8 0.210 
MRC upper limbs (max. 50) 29.6 (13.79); 24.1 to 35.2 27.5 (18.53); 20 to 35 0.636 
MRC lower limbs (max 30) 17.9 (5.42); 15.7 to 20 13 (11.03); 8.5 to 17.4 0.048 
Data are presented as mean (SD); C.I. 95%. P-value for Chi-Square (Sex), and T-Student for independent samples. BMI: Body Mass 3 
Index. ALFSFR-r: Amyotrophic lateral sclerosis functional rating scale. MRC: Medical Research Council Scale for muscular 4 
Strength. P- value for Chi-square test for sex differences and T-Student test for independent samples for age, weight, height and 5 
body mass index differences 6 
 7 
 8 
 9 
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Table 2. Evolution in clinical and first order statistic ultrasound variables. 
US parameters Time Mean (SD) 95% C.I. Minimum Maximum p-value* Effect size** Mean % change 
Clinical variables  
MRC total 
(max. 100) 
Initial 62.9 (19.72) 54.9 to 70.8 31.4 94.6      
10th week 58.3 (23.13) 48.9 to 67.6 12.0 94.6 0.006 0.22 -8.2 
20th week 51.8 (25.46) 41.5 to 62.0 12.0 94.6 0.001 0.56 -20.8 
MRC upper limbs 
(max. 50) 
Initial 29.6 (13.79) 24.1 to 35.2 2.0 46.7    
10th week 27.5 (15.11) 21.4 to 33.6 0.0 46.7 0.009 0.16 -9.4 
20th week 22.9 (16.68) 16.2 to 29.7 0.0 46.7 0.007 0.48 -34.7 
MRC lower limbs 
(max. 30) 
Initial 17.9 (5.42) 15.7 to 20 6.0 28.0    
10th week 15.9 (7.51) 12.9 to 19 0.0 28.0 0.005 0.35 -15.7 
20th week 14.5 (8.02) 11.2 to 17.7 0.0 28.0 <0.001 0.62 -26.5 
ALSFRS-r 
(max. 48) 
Initial 29.3 (11.92) 24.5 to 34.1 5.0 48.0      
10th week 26.5 (12.53) 21.5 to 31.6 5.0 48.0 0.012 0.23 -11.2 
20th week 22.7 (11.34) 18.1 to 27.3 5.0 46.0 <0.001 0.55 -21.3 
Muscle thickness(MTh; mm)  
Biceps/brachialis  
Initial 31.1 (6.13) 28.5 to 33.7 21.4 41.1      
10th week 30.1 (7.24) 27.0 to 33.1 10.0 42.5 0.847 0.20 -6.3 
20th week 28.9 (5.38) 26.6 to 31.1 18.0 39.1 <0.001 0.40 -7.6 
Forearm flexor  
Initial 31.1 (7.89) 27.8 to 34.4 16.4 44.2      
10th week 31.0 (6.63) 28.2 to 33.8 15.6 44.2 1.000 0.05 0.4 
20th week 27.8 (6.55) 25.0 to 30.6 19.2 39.8 0.177 0.43 -7.2 
Quadriceps femoris 
Initial 26.5 (7.84) 23.2 to 29.8 15.6 40.7      
10th week 26.4 (7.08) 23.4 to 29.4 10.4 41.5 1.000 0.04 -0.9 
20th week 24.1 (7.67) 20.8 to 27.3 10.8 35.6 0.095 0.32 -8.5 
Tibialis anterior 
Initial 21.8 (5.73) 19.4 to 24.2 11.3 32.4      
10th week 19.8 (3.83) 18.2 to 21.4 12.4 25.4 0.318 0.32 -1.5 
20th week 19.5 (4.04) 17.7 to 21.2 12.1 27.4 0.034 0.39 -7.1 
Echointensity (EI; 0 – 255 levels)  
Biceps/brachialis  
Initial 87.7 (13.72) 81.9 to 93.5 63.3 120.3      
10th week 102.4 (16.67) 95.4 to 109.5 76.4 143.1 0.001 0.99 17.5 
20th week 108.0 (14.98) 101.7 to 114.4 88.1 151.4 <0.001 1.49 25.8 
Forearm flexor  
Initial 99.3 (16.49) 92.4 to 106.3 66.5 130.1      
10th week 109.2 (14.68) 103.0 to 115.4 82.0 142.1 0.115 0.61 12.0 
20th week 119.0 (13.26) 113.4 to 124.6 94.8 140.9 <0.001 1.22 23.3 
Quadriceps femoris 
Initial 95.6 (15.38) 89.1 to 102.1 74.4 123.9      
10th week 103.0 (13.22) 97.4 to 108.6 79.6 123.2 0.069 0.53 10.3 
20th week 114.3 (15.55) 107.7 to 120.9 81.5 143.8 <0.001 1.22 22.3 
Tibialis anterior 
Initial 110.1 (14.28) 104.1 to 116.1 75.1 129.8      
10th week 114.3 (13.25) 108.7 to 119.8 94.0 137.4 0.618 0.29 4.2 
20th week 116.3 (11.36) 111.5 to 121.1 100.0 134.8 0.096 0.48 7.6 
Echovariation (EV; 0 - 100 points)  
Biceps/brachialis  
Initial 24.5 (7.65) 21.3 to 27.8 9.5 38.3      
10th week 21.1 (4.89) 19.0 to 23.2 11.0 30.5 0.089 0.42 -7.4 
20th week 22.4 (5.47) 20.1 to 24.7 12.6 31.3 0.577 0.27 -0.2 
Forearm flexor  
Initial 19.0 (4.42) 17.1 to 20.9 10.6 26.5      
10th week 21.3 (4.11) 19.6 to 23.1 14.3 29.0 0.173 0.50 9.8 
20th week 22.7 (4.02) 21.0 to 24.4 14.3 31.2 <0.001 0.77 21.6 
Quadriceps femoris 
Initial 16.9 (3.42) 15.5 to 18.4 11.0 24.2      
10th week 21.5 (5.35) 19.3 to 23.8 12.8 33.2 0.005 1.24 22.5 
20th week 22.7 (4.18) 20.9 to 24.4 14.8 29.8 <0.001 1.61 37.7 
Tibialis anterior 
Initial 17.2 (3.92) 15.6 to 18.9 11.5 25.2      
10th week 19.1 (4.45) 17.2 to 21.0 12.3 28.1 0.181 0.54 17.1 
20th week 18.4 (4.35) 16.5 to 20.2 12.8 29.1 0.447 0.40 13.9 
 
S.D: standard deviation. 95% C.I.: 95% confidence interval. * The reference is the initial exploration**Effect size was estimated 
with Cohen’s d Statistic (<0.1 small, 0.25 medium and > 0.4 large effect size). 
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Table 3. Evolution of second order statistical ultrasound variables through Grey Level Co-
occurrence Matrix (GLCM) textural features. 
US parameters Time Mean (SD) 95% C.I. Minimum Maximum p-value* Effect size** Mean % change 
Angular Second Moment (ASM)  
Biceps/brachialis 
Initial 19.4 (8.71) 15.8 to 23.1 8.2 44.0      
10th week 14.7 (6.84) 11.8 to 17.6 6.1 41.0 0.083 0.55 -11.8 
20th week 12.8 (4.04) 11.1 to 14.5 6.3 21.0 0.001 0.76 -25.6 
Forearm flexor  
Initial 15.4 (6.57) 12.6 to 18.1 7.7 31.0      
10th week 11.1 (4.00) 9.4 to 12.8 5.2 21.0 0.040 0.65 -7.5 
20th week 9.8 (2.54) 8.8 to 10.9 6.1 16.0 0.005 0.84 -25.6 
Quadriceps femoris 
Initial 18.3 (8.56) 14.7 to 21.9 7.2 48.0      
10th week 14.0 (5.77) 11.5 to 16.4 6.4 29.0 0.154 0.50 -5.5 
20th week 11.4 (3.65) 9.8 to 12.9 5.7 18.0 0.007 0.81 -25.9 
Tibialis anterior 
Initial 19.4 (8.71) 15.8 to 23.1 8.2 44.0      
10th week 14.7 (6.84) 11.8 to 17.6 6.1 41.0 0.061 0.65 -14.4 
20th week 12.8 (4.04) 11.1 to 14.5 6.3 21.0 0.018 0.65 -18.1 
Contrast (CON)  
Biceps/brachialis  
Initial 194.0 (99.06) 152.2 to 235.8 84.1 517.6      
10th week 229.3 (71.16) 199.3 to 259.4 75.3 365.9 0.087 0.36 39.9 
20th week 228.4 (91.28) 189.9 to 267.0 127.0 535.9 0.540 0.35 32.8 
Forearm flexor  
Initial 210.3 (73.38) 179.4 to 241.3 87.3 335.0      
10th week 247.1 (77.88) 214.2 to 280.0 105.8 447.4 0.388 0.50 24.4 
20th week 289.5 (92.40) 250.4 to 328.5 145.9 486.6 0.010 1.08 58.6 
Quadriceps femoris 
Initial 203.5 (84.39) 167.9 to 239.2 107.5 394.6      
10th week 227.9 (94.05) 188.2 to 267.6 89.4 508.3 1.000 0.29 23.2 
20th week 288.0 (150.67) 224.4 to 351.6 151.9 852.8 0.076 1.00 65.6 
Tibialis anterior 
Initial 263.2 (100.28) 220.9 to 305.6 78.3 476.2      
10th week 304.6 (111.42) 257.5 to 351.6 142.3 554.0 0.100 0.41 21.8 
20th week 312.2 (139.01) 253.5 to 370.9 140.8 601.4 0.192 0.49 28.3 
Textural Correlation (TC)  
Biceps/brachialis  
Initial 18.7 (9.1) 14.9 to 22.6 7.3 47.0      
10th week 16.0 (7.65) 12.8 to 19.2 6.1 38.0 0.639 0.30 1.0 
20th week 14.2 (5.43) 11.9 to 16.5 5.3 26.0 0.085 0.50 -10 
Forearm flexor  
Initial 24.4 (10.21) 20.1 to 28.7 10.3 46.5      
10th week 16.0 (6.25) 13.3 to 18.6 6.3 28.0 0.056 0.59 -7.3 
20th week 12.1 (5.54) 9.8 to 14.5 4.4 30.5 <0.001 0.94 -38 
Quadriceps femoris 
Initial 20.2 (9.31) 16.2 to 24.1 9.3 44.0      
10th week 14.2 (5.13) 12 to 16.3 6.5 27.5 0.005 0.90 -13.9 
20th week 10.6 (3.28) 9.2 to 12 6.0 20.0 <0.001 1.31 -40.2 
Tibialis anterior 
Initial 17.2 (8.16) 13.7 to 20.6 8.0 49.0      
10th week 13.8 (5.21) 11.6 to 16.0 5.8 32.0 0.350 0.41 -9.1 
20th week 14.0 (5.05) 11.8 to 16.1 6.6 24.0 0.268 0.40 -10.2 
Inverse Difference Moment (IDM)  
Biceps/brachialis  
Initial 25.7 (5.28) 23.5 to 28.0 17.7 34.5      
10th week 22.6 (4.50) 20.7 to 24.5 16.2 37.5 0.005 0.60 -9.6 
20th week 22.0 (3.72) 20.4 to 23.6 15.4 28.9 <0.001 0.71 -13.0 
Forearm flexor  
Initial 21.5 (3.97) 19.8 to 23.1 15.7 29.0      
10th week 20.3 (4.76) 18.3 to 22.3 15.2 32.6 1.000 0.29 2.7 
20th week 19.5 (3.35) 18.0 to 20.9 14.5 25.4 0.333 0.51 -5.7 
Quadriceps femoris 
Initial 22.5 (4.12) 20.8 to 24.3 15.5 30.7      
10th week 22.3 (4.65) 20.3 to 24.2 14.0 32.3 1.000 0.06 5.6 
20th week 21.0 (3.84) 19.3 to 22.6 15.7 27.0 0.567 0.38 -4.7 
Tibialis anterior 
Initial 22.3 (4.54) 20.4 to 24.3 14.6 31.4      
10th week 20.0 (4.33) 18.2 to 21.9 14.3 28.6 0.014 0.51 -7.5 
20th week 20.0 (3.57) 18.5 to 21.5 14.6 25.7 0.015 0.52 -10.0 
Entropy (ENT)  
Biceps/brachialis  
Initial 7.0 (0.41) 6.8 to 7.1 5.9 7.7      
10th week 7.1 (0.38) 7.0 to 7.3 6.0 7.8 0.148 0.44 2.5 
20th week 7.2 (0.33) 7.1 to 7.4 6.6 7.9 0.004 0.63 3.7 
 
 
23 
 
US parameters Time Mean (SD) 95% C.I. Minimum Maximum p-value* Effect size** Mean % change 
Forearm flexor  
Initial 7.1 (0.38) 6.9 to 7.2 6.3 7.6      
10th week 7.3 (0.34) 7.2 to 7.5 6.6 8.0 0.097 0.63 2.1 
20th week 7.4 (0.24) 7.3 to 7.5 6.9 7.9 0.005 0.96 5.3 
Quadriceps femoris 
Initial 6.9 (0.40) 6.7 to 7.1 5.9 7.7      
10th week 7.2 (0.38) 7.0 to 7.3 6.4 7.8 0.139 0.59 2.5 
20th week 7.3 (0.34) 7.2 to 7.5 6.8 7.9 0.004 1.01 6.1 
Tibialis anterior 
Initial 6.9 (0.27) 6.8 to 7 6.2 7.5      
10th week 7.1 (0.29) 7.0 to 7.2 6.3 7.5 0.026 0.78 3.0 
20th week 7.1 (0.24) 7.0 to 7.2 6.7 7.5 0.016 0.71 3.4 
S.D: standard deviation. 95% C.I.: 95% confidence interval. * The reference is the initial exploration**Effect size was estimated 
with Cohen’s d Statistic (<0.1 small, 0.25 medium and > 0.4 large effect size). 
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Supplementary Table 1. First order statistics ultrasound variables between the follow-
up group and the lost to follow-up group. 
US parameters Group Mean (SD) 95% C.I. Minimum Maximum p-value Effect size* 
Muscle thickness (MTh; mm) 
Biceps/brachialis 
Follow-up 30.6 (6.21) 28.0 to 33.1 21.4 41.1 
0.021 0.63 
Lost 26.6 (5.93) 24.2 to 28.9 16.6 39.9 
Forearm flexor  
Follow-up 30.4 (7.92) 27.2 to 33.6 16.4 44.2 
0.729 0.10 
Lost 29.5 (11.33) 24.9 to 34.1 18.5 72.0 
Quadriceps femoris 
Follow-up 25.6 (8.1) 22.4 to 28.9 15.1 40.7 
0.027 0.61 
Lost 20.2 (9.13) 16.5 to 23.9 8.1 47.0 
Tibialis anterior 
Follow-up 21.1 (5.95) 18.7 to 23.5 11.3 32.4 
0.007 0.73 
Lost 17.0 (4.43) 15.3 to 18.8 10.1 26.7 
Echointensity (EI; 0 - 255 levels) 
Biceps/brachialis 
Follow-up 88.7 (14.11) 83 to 94.4 63.3 120.3 
0.074 0.49 
Lost 95.8 (14.07) 90.1 to 101.5 66.6 124.2 
Forearm flexor 
Follow-up 99.1 (16.39) 92.5 to 105.8 66.5 130.1 
0.283 0.30 
Lost 103.7 (13.96) 98.1 to 109.4 81.5 131.0 
Quadriceps femoris 
Follow-up 95.3 (15.05) 89.2 to 101.4 74.4 123.9 
0.033 0.59 
Lost 105.8 (19.46) 98.0 to 113.7 78.2 146.1 
Tibialis anterior 
Follow-up 110.1 (13.75) 104.6 to 115.7 75.1 129.8 
0.008 0.72 
Lost 121.9 (16.86) 115.1 to 128.7 92.1 152.1 
Echovariation (EV; 0 - 100 points) 
Biceps/brachialis 
Follow-up 24.3 (7.4) 21.3 to 27.3 9.5 38.3 
0.213 0.35 
Lost 21.7 (7.18) 18.8 to 24.6 10.4 36.8 
Forearm flexor 
Follow-up 19.2 (4.29) 17.4 to 20.9 10.6 26.5 
0.786 0.08 
Lost 19.5 (4.87) 17.5 to 21.5 11.5 30.0 
Quadriceps femoris 
Follow-up 17 (3.29) 15.6 to 18.3 11.0 24.2 
0.001 0.85 
Lost 20.8 (4.73) 18.8 to 22.7 11.2 29.5 
Tibialis anterior 
Follow-up 16.8 (4) 15.2 to 18.5 10.8 25.2 
0.623 0.14 
Lost 16.2 (4.66) 14.4 to 18.1 7.5 26.4 
S.D: standard deviation. 95% C.I.: 95% confidence interval. *Effect size was estimated with Cohen’s d Statistic (<0.1 small, 
0.25 medium and > 0.4 large effect size). 
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Supplementary Table 2. Second order statistical ultrasound variables measured from grey 1 
level co-occurrence matrix (GLCM) between patients with 3 measurements and lost patients 2 
group. 3 
US parameters Group Mean (SD) 95% C.I. Minimum Maximum p-value Effect size* 
Angular Second Moment (ASM) 
Biceps/brachialis 
Follow-up 18.8 (8.63) 15.3 to 22.3 8.2 44.0 
0.823 0.06 
Lost 18.3 (9.09) 14.6 to 21.9 8.5 44.0 
Forearm flexor 
Follow-up 15.3 (6.48) 12.7 to 17.9 7.7 31.0 
0.269 0.31 
Lost 13.4 (5.51) 11.2 to 15.7 6.3 26.5 
Quadriceps femoris 
Follow-up 18.4 (8.27) 15.1 to 21.8 7.2 48.0 
0.008 0.72 
Lost 12.9 (6.12) 10.4 to 15.4 4.8 28.0 
Tibialis anterior 
Follow-up 16.9 (5.50) 14.6 to 19.1 8.2 33.0 
0.557 0.17 
Lost 15.8 (6.99) 13.0 to 18.6 7.6 36.0 
Contrast (CON) 
Biceps/brachialis 
Follow-up 198.6 (96.97) 159.5 to 237.8 84.1 517.6 
0.706 0.11 
Lost 209.6 (111.27) 164.7 to 254.6 74.3 556.6 
Forearm flexor 
Follow-up 207.7 (72.11) 178.6 to 236.8 87.3 335.0 
0.143 0.41 
Lost 240.1 (84.43) 206.0 to 274.2 114.0 451.0 
Quadriceps femoris 
Follow-up 200.9 (82.51) 167.6 to 234.3 107.5 394.6 
0.011 0.69 
Lost 287.0 (143.97) 228.9 to 345.2 103.4 667.8 
Tibialis anterior 
Follow-up 261.0 (97.49) 221.6 to 300.3 78.3 476.2 
0.028 0.60 
Lost 340.1 (149.27) 279.8 to 400.4 173.1 701.4 
Textural Correlation (TC) 
Biceps/brachialis 
Follow-up 18.3 (8.85) 14.8 to 21.9 7.3 47.0 
0.825 0.06 
Lost 17.8 (8.38) 14.4 to 21.2 10.0 46.0 
Forearm flexor 
Follow-up 20.0 (9.05) 16.3 to 23.6 9.3 44.0 
0.267 0.31 
Lost 17.5 (7.06) 14.6 to 20.3 7.1 31.0 
Quadriceps femoris 
Follow-up 24.4 (9.94) 20.4 to 28.4 10.3 46.5 
0.004 0.79 
Lost 16.4 (8.78) 12.9 to 20.0 4.8 35.5 
Tibialis anterior 
Follow-up 17.4 (7.87) 14.2 to 20.6 8.0 49.0 
0.091 0.47 
Lost 14.2 (5.26) 12.1 to 16.3 6.6 26.0 
Inverse Different Moment (IDM) 
Biceps/brachialis 
Follow-up 25.5 (5.17) 23.4 to 27.6 17.7 34.5 
0.954 0.02 
Lost 25.4 (5.92) 23.0 to 27.8 17.3 36.9 
Forearm flexor 
Follow-up 21.5 (3.96) 19.9 to 23.1 15.7 29.0 
0.161 0.39 
Lost 20.0 (3.61) 18.6 to 21.5 15.0 28.3 
Quadriceps femoris 
Follow-up 22.8 (4.09) 21.2 to 24.5 15.5 30.7 
0.064 0.51 
Lost 20.7 (3.82) 19.2 to 22.3 15.1 29.4 
Tibialis anterior 
Follow-up 22.6 (4.48) 20.8 to 24.4 14.6 31.4 
0.204 0.35 
Lost 21.1 (4.28) 19.3 to 22.8 15.1 31.0 
Entropy (ENT) 
Biceps/brachialis 
Follow-up 7.0 (0.41) 6.8 to 7.1 5.9 7.7 
0.925 0.03 
Lost 7.0 (0.46) 6.8 to 7.2 5.9 7.6 
Forearm flexor 
Follow-up 7.1 (0.38) 6.9 to 7.2 6.3 7.6 
0.315 0.28 
Lost 7.2 (0.39) 7.0 to 7.3 6.4 7.8 
Quadriceps femoris 
Follow-up 6.9 (0.39) 6.8 to 7.1 5.9 7.7 
0.004 0.78 
Lost 7.3 (0.44) 7.1 to 7.4 6.4 8.1 
Tibialis anterior 
Follow-up 6.9 (0.28) 6.8 to 7.0 6.2 7.5 
0.391 0.24 
Lost 6.9 (0.36) 6.8 to 7.1 6.0 7.5 
S.D: standard deviation. 95% C.I.: 95% confidence interval. *Effect size was estimated with Cohen’s d Statistic (<0.1 small, 0.25 4 
medium and > 0.4 large size effect). 5 
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